Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 3

The use of antithrombotics in patients presenting with stroke and atrial fibrillation

Authors Carl Burgess, Tristram Ingham, Martin Woodbridge, Mark Weatherall, Michael Nowitz

Published 15 July 2007 Volume 2007:3(3) Pages 491—498

Carl Burgess1, Tristram Ingham1, Martin Woodbridge2, Mark Weatherall1, Michael Nowitz1

1Department of Medicine, Wellington School of Medicine & Health Sciences, Wellington, New Zealand; 2Medsafe, Ministry of Health, 133 Molesworth Street, PO Box 5013, Wellington, New Zealand

Abstract: Antithrombotics have been shown to decrease the risk of stroke in patients with atrial fibrillation (AF). However they are associated with an increased risk of bleeding. We assessed the frequency and appropriateness of antithrombotic therapy in patients admitted to our service with stroke and AF. A retrospective case study of 219 patients (mean age 77.2 years) admitted between January 1999 and 31 December 2001 with a diagnosis of stroke and AF was done. Patient characteristics, presence of comorbid conditions, knowledge of preadmission AF, medication history and appropriateness of antithrombotic treatment were recorded. One hundred and fifty patients were known to have had AF prior to admission. Forty-one presented with an intracranial hemorrhage (19 on warfarin, 10 on aspirin). Of those patients with known AF only 43 were on treatment consistent with the guidelines. Warfarin was recommended in 144 of the whole cohort, but only 39 were taking it. Fifty-three patients were receiving aspirin although warfarin was the recommended treatment. Fifty-four with known AF were not on any antithrombotic treatment. Factors significantly associated with the use of antithrombotic treatment were history of AF (p = 0.0004), valvular heart disease (p = 0.02), venous thromboembolism (p = 0.04), risk of thromboembolism (p = 0.003) and presentation with a nonischemic infarct (p = 0.008). Antithrombotic therapy use in our patients differs significantly from guideline recommendations.

Keywords: aspirin, warfarin, atrial fibrillation

Download Article [PDF] 

Readers of this article also read:

Investigation of cellular responses upon interaction with silver nanoparticles

Subbiah R, Jeon SB, Park K, Ahn SJ, Yun KS

International Journal of Nanomedicine 2015, 10:191-201

Published Date: 27 August 2015

Applications of calixarenes in cancer chemotherapy: facts and perspectives

Yousaf A, Abd Hamid S, Bunnori NM, Ishola AA

Drug Design, Development and Therapy 2015, 9:2831-2838

Published Date: 2 June 2015

Microwave-assisted polyol synthesis of carbon nitride dots from folic acid for cell imaging

Guan WW, Gu W, Ye L, Guo CY, Su S, Xu PX, Xue M

International Journal of Nanomedicine 2014, 9:5071-5078

Published Date: 31 October 2014

Gli3 silencing enhances cyclopamine suppressive effects on ovarian cancer

Liu HY, Dong Z

OncoTargets and Therapy 2014, 7:2007-2011

Published Date: 30 October 2014

Remembering and forgetting: directed forgetting effect in obsessive-compulsive disorder

Konishi M, Shishikura K, Nakaaki S, Komatsu S, Mimura M

Neuropsychiatric Disease and Treatment 2011, 7:365-372

Published Date: 15 June 2011

Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration

Roberto Gallego-Pinazo, Ana Marina Suelves-Cogollos, Ester Francés-Muñoz, et al

Clinical Ophthalmology 2011, 5:161-165

Published Date: 8 February 2011

Vaccination against hepatitis A in children: A review of the evidence

Paolo Bonanni, Sara Boccalini, Angela Bechini

Therapeutics and Clinical Risk Management 2007, 3:1071-1076

Published Date: 15 January 2008

Treatment of non-alcoholic fatty liver disease

Keith G Tolman, Anthony S Dalpiaz

Therapeutics and Clinical Risk Management 2007, 3:1153-1163

Published Date: 15 January 2008